https://orcid.org/0000-0001-5611-5251
References
- Advanced Life Sciences, 2009. FDA briefing document: cethromycin tablets. Available from: www.accessdata.fda.gov
- Bayer HealthCare Pharmaceuticals Inc., 2010. Highlights of prescribing Information: AVELOX (moxifloxacin hydrochloride) Film coated tablet, injection, solution for IV use. Available from: www.accessdata.fda.gov/drugsatfda_docs/label
- Bayer HealthCare Pharmaceuticals Inc., 2016. Highlights of prescribing Information: CIPRO (ciprofloxacin hydrochloride) tablet for oral use, oral suspension. Available from: www.accessdata.fda.gov/drugsatfda_docs/label
- BGP Pharma ULC, 2016. Product monograph: BIAXIN (clarithromycin for oral suspension USP 125 mg/5 mL and 250 mg/5 mL). Available from: www.accessdata.fda.gov/drugsatfda_docs/label
- Cempra Pharmaceuticals Inc., 2016. FDA briefing document: solithromycin for CABP. Available from: www.accessdata.fda.gov
- Chavan, R., et al., 2016. WCK 4873 (Nafithromycin): assessment of in vitro human CYP inhibitory potential of a novel lactone-ketolide. Open forum infectious diseases, 3, 1808.
- Chavan, R., et al., 2020. Assessment of in vitro inhibitory effects of novel anti MRSA benzoquinolizine fluoroquinolone WCK 771 (levonadifloxacin) and its metabolite on human liver cytochrome P450 enzymes. Xenobiotica, 50, 1149–1157.
- Douthwaite, S., 2001. Structure–activity relationships of ketolides vs. macrolides. Clinical microbiology and infection, 7, 11–17.
- Elsby, R., et al., 2019. Mechanistic in vitro studies indicate that the clinical drug–drug interaction between telithromycin and simvastatin acid is driven by time-dependent inhibition of CYP3A4 with minimal effect on OATP1B1. Drug metabolism and disposition : the biological fate of chemicals, 47, 1–8.
- Fernandes, P., Martens, E., and Pereira, D., 2017. Nature nurtures the design of new semi-synthetic macrolide antibiotics. The Journal of antibiotics, 70, 527–533.
- Filppula, A.M., et al., 2019. Improved predictions of time-dependent drug–drug interactions by determination of cytosolic drug concentrations. Scientific Reports, 9, 5850.
- Flamm, R.K., Rhomberg, P.R., and Sader, H.S., 2017. In vitro activity of the novel lactone ketolide nafithromycin (WCK 4873) against contemporary clinical bacteria from a global surveillance program. Antimicrobial agents and chemotherapy, 61, e01230-17.
- Iwanowski, P., et al., 2019. Safety, tolerability and pharmacokinetics of oral nafithromycin (WCK4873) after single or multiple doses and effects of food on single-dose bioavailability in healthy adult subjects. Antimicrobial agents and chemotherapy, 63, e01253-19.
- Jamieson, B.D., Ciric, S., and Fernandes, P., 2015. Safety and pharmacokinetics of solithromycin in subjects with hepatic impairment. Antimicrobial agents and chemotherapy, 59, 4379–4386.
- Krokidis, M.G., et al., 2014. Insights into the mode of action of novel fluoroketolides, potent inhibitors of bacterial protein synthesis. Antimicrobial agents and chemotherapy, 58, 472–480.
- Leucuta, S.E., Vlase, L., 2006. Pharmacokinetics and metabolic drug interactions. Current clinical pharmacology, 1, 5–20.
- Parkinson, A., et al., 2011. An evaluation of the dilution method for identifying metabolism-dependent inhibitors of cytochrome P450 enzymes. Drug metabolism and disposition : the biological fate of chemicals, 39, 1370–1387.
- Pfizer Canada Inc., 2012. Prescribing information: ERYC (Erythromycin delayed release capsules USP). Available from: www.accessdata.fda.gov/drugsatfda_docs/label
- Pfizer Canada Inc., 2013. Product monograph: ZITHROMAX (azithromycin dihydrate Tablets 250 mg, 500 mg and 600 mg. Powder for Oral Suspension 100 mg/5 mL and 200 mg/5 mL USP. For Injection 500 mg per vial (100 mg/mL) Intravenous Infusion after reconstitution. Available from: www.accessdata.fda.gov/drugsatfda_docs/label
- Rodvold, K.A., et al., 2017. Comparison of plasma and intrapulmonary concentrations of nafithromycin (WCK 4873) in healthy adult subjects. Antimicrobial agents and chemotherapy, 61, e01096-17.
- Sekiguchi, N., et al., 2009. Prediction of drug–drug interactions based on time-dependent inhibition from high throughput screening of cytochrome P450 3A4 inhibition. Drug metabolism and pharmacokinetics, 24, 500–510.
- Shakeri-Nejad, K. and Stahlmann, R., 2006. Drug interactions during therapy with three major groups of antimicrobial agents. Expert opinion on pharmacotherapy, 7, 639–651.
- Van Bambeke, F., et al., 2008. Ketolides: pharmacological profile and rational positioning in the treatment of respiratory tract infections. Expert Opinion on Pharmacotherapy, 9 (2), 267–283.
- Westphal, J.F., 2000. Macrolide-induced clinically relevant drug interactions with cytochrome P-450A (CYP) 3A4: an update focused on clarithromycin, azithromycin and dirithromycin. British journal of clinical pharmacology, 50, 285–295.